Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice

Journal of Autoimmunity

Volumn 33, Issue 2, 2009, Pages 83-91

  Kaminitz, Ayelet ^a   Mizrahi, Keren ^a   Yaniv, Isaac ^a   Farkas, Daniel L ^b   Stein, Jerry ^a   Askenasy, Nadir ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Bone marrow transplant; NOD; Syngeneic; Type 1 diabetes

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE INSULITIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; HISTOCOMPATIBILITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS; PRIORITY JOURNAL; THERAPY EFFECT; WHOLE BODY RADIATION;

AGE FACTORS; ANIMALS; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CHIMERISM; DIABETES MELLITUS, TYPE 1; FEMALE; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PREDIABETIC STATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 68249109933     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.07.001     Document Type: Article

References (77)

1. Guo Z., Wu T., Kirchhof N., Mital D., Williams J.W., Azuma M., et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation 71 (2001) 1656-1665
2. Okitsu T., Bartlett S.T., Hadley G.A., Drachenberg C.B., and Farney A.C. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant 1 (2001) 138-145
3. Makhlouf L., Kishimoto K., Smith R.N., Abdi R., Koulmanda M., Winn H.J., et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 51 (2002) 3202-3210
4. Kupfer T.M., Crawford M.L., Pham K., and Gill R.G. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J Immunol 175 (2005) 2309-2316
5. Iskovich S., Kaminitz A., Yafe M.P., Mizrahi K., Stein J., Yaniv I., et al. Participation of adult bone marrow-derived stem cells in pancreatic regeneration: neogenesis versus endogenesis. Curr Stem Cell Res Ther 2 (2007) 272-279
6. Good R.A. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases. World J Surg 24 (2000) 797-810
7. Ikehara S. Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol 29 (2001) 661-669
8. Burt R.K., Slavin S., Burns W.H., and Marmont A.M. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 99 (2002) 768-784
9. Sykes M., and Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 435 (2005) 620-627
10. Ikehara S., Ohtsuki H., Good R.A., Asamoto H., Nakamura T., Sekita K., et al. Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 82 (1985) 7743-7747
11. Colson Y.L., Li H., Boggs S.S., Patrene K.D., Johnson P.C., and Ildstad S.T. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 157 (1996) 2820-2829
12. Li H., Kaufman C.L., Boggs S.S., Johnson P.C., Patrene K.D., and Ildstad S.T. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol 156 (1996) 380-388
13. Kaufman C.L., Li H., and Ildstad S.T. Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow. J Immunol 158 (1997) 2435-2442
14. Beilhack G.F., Scheffold Y.C., Weissman I.L., Taylor C., Jerabek L., Burge M.J., et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 52 (2003) 59-68
15. Zorina T.D., Subbotin V.M., Bertera S., Alexander A.M., Haluszczak C., Gambrell B., et al. Recovery of the endogenous ß cell function in the NOD model of autoimmune diabetes. Stem Cells 21 (2003) 377-388
16. Nikolic B., Takeuchi Y., Leykin I., Fudaba Y., Smith R.N., and Sykes M. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 53 (2004) 376-383
17. Elkin G., Prigozhina T.B., and Slavin S. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 32 (2004) 579-584
18. Ildstad S.T., Chilton P.M., Xu H., Domenick M.A., and Ray M.B. Preconditioning of NOD mice with anti-CD8 mAb and costimulatory blockade enhances chimerism and tolerance and prevents diabetes, while depletion of alpha beta-TCR+ and CD4+ cells negates the effect. Blood 105 (2004) 2577-2584
19. Kang E.M., Zickler P.P., Burns S., Langemeijer S.M., Brenner S., Phang O.A., et al. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol 33 (2005) 699-705
20. Tian C., Ansari M.J., Paez-Cortez J., Bagley J., Godwin J., Donnarumma M., et al. Induction of robust diabetes resistance and prevention of recurrent type 1 diabetes following islet transplantation by gene therapy. J Immunol 179 (2007) 6762-6769
21. Li H., Colson Y.L., and Ildstad S.T. Mixed allogeneic chimerism achieved by lethal and nonlethal conditioning approaches induces donor-specific tolerance to simultaneous islet allografts. Transplantation 60 (1995) 523-529
22. Wu T., Levay-Young B., Heuss N., Sozen H., Kirchhof N., Sutherland D.E., et al. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation 74 (2002) 22-27
23. Carroll P.B., Fontes P., Rao A.S., Ricordi C., Rilo H.L., Zeevi A., et al. Simultaneous solid organ, bone marrow, and islet allotransplantation in type I diabetic patients. Transplant Proc 26 (1994) 3523-3524
24. Corry R.J., Chakrabarti P.K., Shapiro R., Rao A.S., Dvorchik I., Jordan M.L., et al. Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg 230 (1999) 372-381
25. Nelson J.L., Torrez R., Louie F.M., Choe O.S., Storb R., and Sullivan K.M. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol 48 Suppl (1997) 23-29
26. Gratwohl A. Activity survey and historical perspective of autologous stem cell transplantation in Europe. Semin Hematol 44 (2007) 220-226
27. Passweg J., and Tyndall A. Autologous stem cell transplantation in autoimmune diseases. Semin Hematol 44 (2007) 278-285
28. Mancardi G., and Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7 (2008) 626-636
29. Slavin S., Kurkalli B.G., and Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 110 (2008) 943-946
30. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., et al. Autologous hematopoietic stem cell transplantation for type 1 diabetes. Ann NY Acad Sci 1150 (2008) 220-229
31. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297 (2007) 1568-1576
32. Couri C.E., Oliveria M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301 (2009) 1573-1579
33. Haller M.J., Viener H.L., Wasserfall C., Brusko T., Atkinson M.A., and Schatz D.A. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 36 (2008) 710-715
34. Zhang C., Todorov I., Lin C.L., Atkinson M., Kandeel F., Forman S., et al. Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci U S A 104 (2007) 2337-2342
35. Pearl-Yafe M., Yolcu E.S., Stein J., Kaplan O., Shirwan H., Yaniv I., et al. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 35 (2007) 1601-1612
36. Hess D., Li L., Martin M., Sakano S., Hill D., Strutt B., et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 21 (2003) 763-770
37. Lee R.H., Seo M.J., Reger R.L., Spees J.L., Pulin A.A., Olson S.D., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 103 (2006) 17438-17443
38. Sachs D.H., and Bonner-Weir S. New islets from old. Nat Med 6 (2000) 250-251
39. Seaberg R.M., Smukler S.R., Kieffer T.J., Enikolopov G., Asghar Z., Wheeler M.B., et al. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol 22 (2004) 1115-1124
40. Wicker L.S., Miller B.J., Chai A., Terada M., and Mullen Y. Expression of genetically determined diabetes and insulitis in the nonobese diabetic (NOD) mouse at the level of bone marrow-derived cells: transfer of diabetes and insulitis to nondiabetic (NOD X B10) F1 mice with bone marrow cells from NOD mice. J Exp Med 167 (1988) 1801-1810
41. Kaminitz A., Stein J., Yaniv I., and Askenasy N. The vicious cycle of apoptotic beta-cell death in type 1 diabetes. Immunol Cell Biol 85 (2007) 582-589
42. Bagley J., Tian C., Sachs D.H., and Iacomini J. T cells mediate resistance to genetically modified bone marrow in lethally irradiated recipients. Transplantation 74 (2002) 1454-1460
43. Pearl-Yafe M., Iskovich S., Kaminitz A., Stein J., Yaniv I., and Askenasy N. Does physiological beta cell turnover initiate autoimmune diabetes in the regional lymph nodes?. Autoimmun Rev 5 (2006) 338-343
44. Shoda L.K., Young D.L., Ramanujan S., Whiting C.C., Atkinson M.A., Bluestone J.A., et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23 (2005) 115-126
45. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., Schatz D.A., and Atkinson M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54 (2005) 1407-1414
46. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., and Tree T.I. Defective suppressor function in CD4(+) CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
47. Gregg R.K., Jain R., Schoenleber S.J., Divekar R., Bell J.J., Lee H.H., et al. A sudden decline in active membrane bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol 173 (2004) 7308-7316
48. Tritt M., Sgouroudis E., d'Hennezel E., Albanese A., and Piccirillo C.A. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 57 (2008) 113-123
49. Roep B.O. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann N Y Acad Sci 1103 (2007) 1-10
50. Guo Z., Wu T., Sozen H., Pan Y., Heuss N., Kalscheuer H., et al. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice. Transplantation 75 (2003) 909-915
51. Burt R.K., Testori A., Craig R., Cohen B., Suffit R., and Barr W. Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned?. J Autoimmun 30 (2008) 116-120
52. Brocker T., Riedinger M., and Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 185 (1997) 541-550
53. Kishimoto H., and Sprent J. A defect in central tolerance in NOD mice. Nat Immunol 2 (2001) 1025-1031
54. Lesage S., Hartley S.B., Akkaraju S., Wilson J., Townsend M., and Goodnow C.C. Failure to censor forbidden clones of CD4 T cells in autoimmune diabetes. J Exp Med 196 (2002) 1175-1188
55. Serreze D.V., Osborne M.A., Chen Y.G., Chapman H.D., Pearson T., Brehm M.A., et al. Partial versus full allogeneic hemopoietic chimerization is a preferential means to inhibit type 1 diabetes as the latter induces generalized immunosuppression. J Immunol 177 (2006) 6675-6684
56. Takaki T., Hosaka N., Miyake T., Cui W., Nishida T., Inaba M., et al. Presence of donor-derived thymic epithelial cells in [B6->MRL/lpr] mice after allogeneic intra-bone marrow-bone marrow transplantation (IBM-BMT). J Autoimmun 31 (2008) 408-415
57. Kupfer T.M., Crawford M.L., Pham K., and Gill R.G. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J Immunol 175 (2005) 2309-2316
58. Seung E., Iwakoshi N., Woda B.A., Markees T.G., Mordes J.P., Rossini A.A., et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versushost disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 95 (2000) 2175-2182
59. Askenasy N., Yolcu E.S., Yaniv I., and Shirwan H. Fas-ligand as a double-edged immunomodulator to induce transplantation tolerance. Blood 105 (2005) 1396-1404
60. Orloff S.L., Yin Q., Corless C.L., Orloff M.S., Rabkin J.M., and Wagner C. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation 69 (2000) 1295-1303
61. Kawai T., Abrahamian G., Sogawa H., Wee S., Boskovic S., Andrew D., et al. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Transplant Proc 33 (2001) 221-222
62. Deane S., Meyers F.J., and Gershwin M.E. On reversing the persistence of memory: hematopoietic stem cell transplant for autoimmune disease in the first ten years. J Autoimmun 30 (2008) 180-196
63. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 3 (2003) 253-257
64. Tang Q., and Bluestone J.A. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 212 (2006) 217-237
65. Yarkoni S., Kaminitz A., and Askenasy N. Mechanisms of T regulatory cell function. Autoimmun Rev 7 (2008) 370-375
66. Yarkoni S., Kaminitz A., Sagiv Y., Yaniv I., and Askenasy N. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. BioEssays 30 (2008) 875-888
67. Steiner D., Brunicki N., Blazar B.R., Bachar-Lustig E., and Reisner Y. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells. Exp Hematol 34 (2006) 66-71
68. Ozawa K., Sato K., Oh I., Ozaki K., Uchibori R., Obara Y., et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 30 (2008) 121-127
69. Payne N., Siatskas C., and Bernard C.C. The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun 31 (2008) 288-294
70. Askenasy N. Localized bone marrow transplantation leads to skin allograft acceptance in nonmyeloablated recipients: comparison of intra-bone marrow and isolated limb perfusion. Stem Cells 20 (2002) 86-93
71. Ikehara S. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J Autoimmun 30 (2008) 108-115
72. Sonoda Y. Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection. J Autoimmun 30 (2008) 136-144
73. Chatenoud L., Primo J., and Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158 (1997) 2947-2954
74. Ratajczak M.Z., Zuba-Surma E.K., Wysoczynski M., Wan W., Ratajczak J., Wojakowski W., et al. Hunt for pluripotent stem cell - regenerative medicine search for almighty cell. J Autoimmun 30 (2008) 151-162
75. Pearl-Yafe M., Yolcu E.S., Yaniv I., Stein J., Shirwan H., and Askenasy N. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays 28 (2006) 211-222
76. Marmont A.M. Will hematopoietic stem cell transplantation cure human autoimmune diseases?. J Autoimmun 30 3 (2008 May) 145-150
77. Verda L., Kim D.A., Ikehara S., Statkute L., Bronesky D., Petrenko Y., et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 26 (2008) 381-386